What Immix Biopharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 0 | 0 |
| Total trades | 0 | 10 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 201,266 |
| Disposed | 0 | 0 |
| Net activity | +0 | +201,266 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Buchan Melissa Jane | Director | May 22 | Grant / award · A | +6,250 | — | — | 28,705 |
| Chang Nancy T | Director | May 22 | Grant / award · A | +6,250 | — | — | 428,190 |
| Chudnovsky Yekaterina | Director | May 22 | Grant / award · A | +6,250 | — | — | 6,250 |
| Marquet Magda | Director | May 22 | Grant / award · A | +6,250 | — | — | 52,342 |
| Adams Helen C. | Director | May 22 | Grant / award · A | +6,250 | — | — | 181,004 |
| Ng Carey | Director | May 22 | Grant / award · A | +6,250 | — | — | 26,250 |
| Hsu Jason | Director | May 22 | Grant / award · A | +6,250 | — | — | 899,250 |
| Morris Gabriel S | CFO | Dec 10 | Open-market buy · P | +770 | $6.58 | +$5.07K | 291,429 |
| Rachman Ilya M | CEO and Chairman | Dec 10 | Open-market buy · P | +746 | $6.67 | +$4.98K | 1,141,683 |
| Morris Gabriel S | CFO | Dec 08 | In/At-money Exercise · X | +156,000 | $0.80 | +$125K | 426,844 |
| Rachman Ilya M | CEO and Chairman | Sep 17 | Open-market buy · P | +2,500 | $2.02 | +$5.05K | 1,140,937 |
| Morris Gabriel S | CFO | Sep 16 | Open-market buy · P | +2,600 | $1.97 | +$5.12K | 290,659 |
| Morris Gabriel S | CFO | Jun 18 | Open-market buy · P | +2,225 | $2.28 | +$5.07K | 288,059 |
| Rachman Ilya M | CEO and Chairman | Jun 18 | Open-market buy · P | +2,178 | $2.30 | +$5K | 1,138,437 |
| Hsu Jason | Director | Dec 23 | Open-market buy · P | +40,000 | $2.19 | +$87.7K | 893,000 |
| Hsu Jason | Director | Dec 20 | Open-market buy · P | +7,700 | $2.17 | +$16.7K | 853,000 |
| Hsu Jason | Director | Aug 22 | Open-market buy · P | +8,100 | $2.25 | +$18.2K | 845,300 |
| Hsu Jason | Director | Aug 21 | Open-market buy · P | +15,000 | $2.23 | +$33.4K | 837,200 |
| Ng Carey | Director | Aug 16 | Open-market buy · P | +10,000 | $1.86 | +$18.6K | 20,000 |
| Hsu Jason | Director | Jul 24 | Open-market buy · P | +6,000 | $2.15 | +$12.9K | 822,200 |
Loading...
